GoodRx (GDRX) Competitors

GoodRx (NASDAQ:GDRX) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, community ranking, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

Do institutionals and insiders believe in GDRX or CORT?

63.8% of GoodRx shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 1.4% of GoodRx shares are held by insiders. Comparatively, 19.8% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Is GDRX or CORT more profitable?

Corcept Therapeutics has a net margin of 21.86% compared to GoodRx's net margin of -1.18%. Corcept Therapeutics' return on equity of 21.98% beat GoodRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GoodRx	-1.18%	2.45%	1.25%
Corcept Therapeutics	21.86%	21.98%	17.89%

Which has higher valuation and earnings, GDRX or CORT?

Corcept Therapeutics has lower revenue, but higher earnings than GoodRx. GoodRx is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GoodRx	$750.27M	3.54	-$8.87M	-$0.02	-336.33
Corcept Therapeutics	$482.38M	4.97	$106.14M	$0.95	24.36

Which has more risk & volatility, GDRX or CORT?

GoodRx has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.

Does the media favor GDRX or CORT?

In the previous week, Corcept Therapeutics had 7 more articles in the media than GoodRx. MarketBeat recorded 12 mentions for Corcept Therapeutics and 5 mentions for GoodRx. Corcept Therapeutics' average media sentiment score of 0.80 beat GoodRx's score of 0.14 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GoodRx	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corcept Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer GDRX or CORT?

GoodRx presently has a consensus price target of $8.78, indicating a potential upside of 30.43%. Corcept Therapeutics has a consensus price target of $37.30, indicating a potential upside of 59.95%. Given Corcept Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than GoodRx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GoodRx	1 Sell rating(s)	8 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.47
Corcept Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community believe in GDRX or CORT?

Corcept Therapeutics received 458 more outperform votes than GoodRx when rated by MarketBeat users. Likewise, 70.42% of users gave Corcept Therapeutics an outperform vote while only 36.53% of users gave GoodRx an outperform vote.

Company	Underperform	Outperform
GoodRx	Outperform Votes 61 36.53%	Underperform Votes 106 63.47%
Corcept Therapeutics	Outperform Votes 519 70.42%	Underperform Votes 218 29.58%

Summary

Corcept Therapeutics beats GoodRx on 15 of the 18 factors compared between the two stocks.